NP001 failed to meet endpoints in a phase II clinical trial. But a post hoc analysis suggested evidence of potential benefit in a small subset of people with ALS. We are hopeful that the upcoming phase III trial will be designed and powered in a way that enables assessment of efficacy. However, we continue to urge caution in the reliance on historical controls and post hoc analysis alone to support advancement of any drug through the clinical trial process.